Nash Treatment

This video presents a comprehensive review of non-alcoholic fatty liver disease (NAFLD) & non-alcoholic steatohepatitis (NASH), delivered by international experts with a multidisciplinary approach: Dr. Maarten Tushuizen, Prof. A.G (Onno) Holleboom, and Prof. Sven Francque, along with chair, Prof. Stefan Anker. They review the epidemiology of NAFLD / NASH, its increasing prevalence rates, and discuss current best practices to improve patient outcomes.

In this video, Prof. Sven Francque (Belgium) discusses how vascular mechanisms contribute to non-alcoholic fatty liver disease (NAFLD) and how non-alcoholic steatohepatitis (NASH) contributes to cardiovascular disease (CVD). He also mentions that drugs used to prevent/treat CVD and NAFLD/NASH are safe and those that are used to prevent/treat CVD can have some benefits for NAFLD.

Prof. Onno Holleboom reviews the strong co-occurence of non-alcoholic fatty liver disease (NAFLD) and atherosclerotic cardiovascular (CVD) disease in this video along with joint pathophysiological pathways and its shared drivers. He further looks into NAFLD and its relationships and effects with atherosclerotic CVD and heart failure. For clinicians, he provides an analyses of the management and diagnosis options for advanced NAFLD.  

Prof. Maarten Tushuizen provides a comprehensive review on Non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD) and why it is a multisystem disease and further goes on to evaluate their connection to type 2 diabetes mellitus (T2DM) and cardiovascular disease. He also delves into the next steps of managing and diagnosing NASH and NAFLD.

Prof. A.G.(Onno) Holleboom, Netherlands, discusses non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) as a metabolic disease and reviews management strategies in order to improve patients outcomes.

Pr Zelber Sagi explains there is an option for life's treatment at each stage of non-alcoholic fatty liver disease NAFLD with lifestyle examples in clinical practice.

Currently, there are no Food and Drug Administration (FDA)-approved or European Medicines Agency (EMA)-approved therapies for NASH and only lifestyles interventions are recommended for the treatment of NAFLD. Prof Zelber-Sagi (Haifa, Israel) reviews best practices for lifestyle interventions in patients with NAFLD. She warns us against ultra-processed foods and drinks, that are so common in the Western world. She also highlights the benefits of the Mediterranean diet and physical activity.